Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1834
https://www.valueinhealthjournal.com/article/S1098-3015(13)03739-X/fulltext
Title : Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03739-X&doi=10.1016/j.jval.2013.08.1834
First page : A624
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 1672
Categories :
Tags :
Regions :
ViH Article Tags :